NCT04144023View on ClinicalTrials.gov

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

PHASE1RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Ductal Carcinoma In Situ
Interventions
BIOLOGICAL

Granulocyte-Macrophage Colony-Stimulating Factor

Given intradermally

BIOLOGICAL

Multi-epitope HER2 Peptide Vaccine H2NVAC

Given intradermally

PROCEDURE

Therapeutic Conventional Surgery

Undergo standard of care surgery

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Biopsy

Undergo biopsy

Trial Locations (2)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04144023 - A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | Biotech Hunter | Biotech Hunter